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Abstract Recent years have seen a tremendous develop-
ment of our insight into the biology of atherosclerosis and
its acute thrombotic manifestations. Inflammation now takes
center stage among traditional risk factors as a decisive
factor in cardiovascular risk. Consequently, its assessment
and modulation have become key to clinical care and fun-
damental research alike. Plaque macrophages orchestrate
many of the inflammatory processes that occur throughout
atherogenesis. These cells are characteristically heteroge-
neous and adopt diverse activation states in response to
micro-environmental triggers. In this review, macrophage-
mediated inflammation in atherosclerosis sets the scene for a
discussion of the gene regulatory mechanisms that facilitate
and shape polarized macrophage phenotypes. When appli-
cable, we consider these factors within the context of
atherosclerosis and reflect on opportunities for future
application.
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Introduction
Myocardial infarction and stroke remain among the leading
causes of death and disease worldwide [1, 2]. To mitigate risk
of these atherosclerotic complications, primary and secondary
prevention strategies seek to correct aberrant blood cholesterol
levels. Actively reducing low-density lipoprotein (LDL) cho-
lesterol through lipid-modifying therapy (eg, statins) yields a
proportional decrease in cardiovascular disease (CVD) risk
[3]. However, there exists a considerable burden of residual
risk, as current treatment strategies cannot prevent 75 % of
major coronary events from occurring [4, 5]. Moreover, indi-
viduals afflicted byCVD are oftentimesfreeoftraditionalrisk
factors [6], suggesting other dynamics contribute to plaque
complication.
In this context, macrophage-mediated inflammation is
paramount, contributing to atherosclerotic plaque initiation
and progression through a variety of mechanisms [7]. We
are developing a better understanding of the processes that
regulate the induction and function of distinct macrophage
subsets and their potential relevance in atherosclerosis. This
review serves to highlight the cellular mediators that convert
environmental cues to a heterogeneous array of functional
macrophage phenotypes, thereby shaping inflammatory
responses in health and disease.
Inflammation and Atherosclerosis
Over the past two decades, the inflammatory hypothesis of
atherothrombosis has gained an increasingly strong footing
through multiple lines of supportive evidence. Overall, an
increased systemic burden of inflammation prompts a higher
CVD incidence, as is the case in chronic inflammatory
conditions such as rheumatic arthritis [8] and systemic lupus
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matory response have been found to predict future cardio-
vascular risk in atherosclerotic patients (well-described in
[10]). High-sensitivity C-reactive protein (hsCRP) has
formed a focus point in this respect, as systemic concen-
trations of this acute-phase protein compared favorably with
LDL cholesterol and blood pressure as CVD risk factors
[11], and were specifically associated to plaque vulnerability
[12, 13]. Building on post hoc analyses from several other
large-scale studies (eg, CARE, PROVE-IT TIMI 22,
AFCAPS/TexCAPS trials [14–16]), the JUPITER trial pro-
spectively consolidated the correlation of hsCRP and car-
diovascular outcome in a primary prevention setting [17].
Researchers observed that the clinical benefits of statin
therapy were greatest when both LDL and hsCRP values
were reduced, thus connecting both dyslipidemia and in-
flammation at the interface of CVD pathogenesis. Intrigu-
ingly, even with pre-existent LDL levels below the clinical
cut-off point for treatment, persistent inflammation as mea-
sured by increased hsCRP levels puts patients at a higher
than anticipated risk of CVD. In the AFCAPS/TexCAPS
trial, these subjects responded strongly to treatment [16],
indicating LDL burden is not a prerequisite to successful
therapy. Apart from providing clinicians with valuable in-
formation for risk assessment, this finding proposes that an
enhanced inflammatory state might in itself justify targeted
therapy. Indeed, US and Canadian prevention guidelines
have since embraced hsCRP measurements in the consider-
ations for patients at intermediate risk. Moreover, a number
of new trials, using either low-dose methotrexate (CIRT) or
anti-IL-1β monoclonal antibodies (CANTOS) as
anti-inflammatory treatment, are underway to address and
possibly validate the hypothesis of inflammatory causality
[18￿, 19￿]. These translational efforts could provide a major
argument towards a more systematic implementation of anti-
inflammatory therapy in our continuing battle to diminish
residual cardiovascular risk.
Substantial experimental evidence complements the
broad clinical involvement of inflammation in CVD out-
lined above. Now most agree that systemic risk factors
interact with many cell types (both those intrinsic to the
vasculature and immune cells attracted from the circulation)
to drive plaque development. Particularly, monocyte-
derived macrophages are considered critical participants in
the atherogenic process, as they secrete pro-inflammatory
cytokines and other mediators that affect lesion progression
and stability. Consequently, many experimental studies have
successfully targeted the abundance of monocytes/macro-
phages and their soluble repertoire in atherosclerosis as a
means of prevention. For instance, atherosclerotic plaque
formation was virtually abolished in hyperlipidemic mice
lacking the macrophage-colony stimulating factor (M-CSF)
gene, which exhibit impaired monocyte development and
subsequent differentiation to macrophages [20, 21]. Other
scientific efforts involved the abrogation of chemokine-
dependent monocyte recruitment to the plaque [22], in ad-
dition to a wealth of studies addressing the various cyto-
kines produced by macrophages and other cells (reviewed in
[23]). Although not cell-specific, these data still offer valu-
able insight into how macrophages contribute to nascent
lesions. Macrophage apoptosis is another important feature
seen during atherosclerosis development. In early lesions,
macrophage apoptosis and plaque size exist in an inverse
relationship [24], whereas in later stages this process con-
tributes to the plaque’s lipid core [25]. This ambiguity
appears to be mediated by a process termed “efferocytosis”
[26]. Combined with proof linking plaque macrophages to
matrix metalloproteinase (MMP)-dependent collagen break-
down [27, 28], it is evident that these cells modulate inflam-
matory mechanisms to determine plaque susceptibility to
rupture and clinical atherothrombosis. Associative imaging
studies lend weight to this notion by demonstrating that
vascular uptake of fluorodeoxyglucose (
18F-FDG) correlates
to plaque macrophage load and general inflammatory burden
and can thereby assist in the prediction of cardiovascular
events [29, 30].
Phenotypic Differences Between Macrophage Subsets
Cultured and tissue macrophages both exhibit pronounced
heterogeneity, as was recognized early on [31]. Skewing of
macrophages toward distinct polarization programs occurs
in response to various environmental cues and has inspired
extensive research into their significance in pathophysiolo-
gy. Reflecting the Th1 and Th2 nomenclature in T-cells,
polarized macrophage subsets were originally referred to
as classically (M1) or alternatively activated (M2) [32].
The latter group was subsequently divided into M2a, M2b,
M2c and tumor-associated macrophages (TAMs) to distin-
guish between inducing stimuli [33]. Later on, Mosser and
Edwards [34] reassigned these macrophage subsets to three
different classes: classically activated macrophages (CAMs,
corresponding to M1), alternative activated macrophages
(AAMs, also referred to as wound healing macrophages
and analogous to M2a), and regulatory macrophages
(RMs, consistent with M2b/c). These classes are best con-
sidered a continuum of functional states that encompasses a
broad range of macrophage phenotypes with interchange-
able characteristics.
CAMs are typically induced by the Th1-cytokine
interferon-γ (IFNγ), possibly followed by activation with a
Toll-like Receptor (TLR) ligand, such as lipopolysaccharides
(LPS).IFNγ(originallytermedmacrophage-activatingfactor)
prepares macrophages for a pro-inflammatory environment,
giving rise to a potent inflammatory response upon microbial
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high interleukin-12 (IL-12) and low IL-10 production, com-
bined with enhanced microbicidal effector functions through
the induction of NADPH-oxidases and inducible nitric oxide
synthase (iNOS). Therefore, these macrophages become very
efficient in killing bacteria, viruses, parasites, and fungi. Their
continuous induction and sustained activation, however, will
cause tissue damage [35].
The Th2 cytokines IL-4 and IL-13 are produced by gran-
ulocytes, mast cells, and Th2 cells during injury and infection
and generate AAMs [36, 37]. Opposite to CAMs, AAMs
dampen inflammatory responses through an IL-12
low and
IL-10
high expression profile. Furthermore, AAMs promote
tissue repair and fibrosis through increased arginase-1-
dependent production of the collagen precursors ornithine
and proline [38].Besides arginase-1, other markers for AAMs
include Ym1, Fizz1, and the mannose receptor (MR).
Finally, regulatory macrophages (RMs) are induced in
response to a wide range of stimuli, including immune com-
plexes, prostaglandins, G-protein coupled receptor ligands,
glucocorticoids, and uptake of apoptotic cells. However, a
key cytokine in the induction of RMs is the anti-
inflammatory, atheroprotective cytokine IL-10. The main task
of RMs is to suppress and control immune responses by
producing high levels of IL-10 and thereby contribute to the
resolution of inflammatory responses [34, 39].
Macrophage Differentiation and Polarization
The current framework of macrophage subsets is very well
characterized in vitro but less so in in vivo settings. Here, a
greater variety of external challenges elicit macrophage
phenotypes that are considerably less adherent to the con-
straints of the existing paradigm. During monocyte-to-
macrophage differentiation and subsequent macrophage acti-
vation, the collective imprint of these environmental factors
shapes the macrophage phenotype. An intuitive overview of
these sequences was recently described by Gordon and
Martinez [40].
First, monocyte recruitment from the circulation will be
followed by differentiation to mature tissue macrophages.
This transition is primarily mediated by the growth factors
M-CSF and granulocyte-macrophage colony-stimulating
factor (GM-CSF) that influence the inflammatory potential
of the resulting macrophage. Maturation with M-CSF was
observed to lead to a more anti-inflammatory (IL-10
highIL-
12
low) phenotype, whereas GM-CSF-induced differentiation
gave rise to a macrophage population with pro-inflammatory
(IL-10
lowIL-12
high) characteristics [41, 42].
The phenotype that ensues from the subsequent priming
stage hinges on the local balance of cytokines and chemo-
kines in the newly recruited macrophage’s environment.
Priming with cytokine stimuli will affect the inflammatory
potential of macrophages and their response to other stimuli.
In addition to the previously described cytokine stimuli
(IFNγ, IL-4/IL-13, and IL-10 for CAMs, AAMs, and RM,
respectively), chemokines (eg, CXCL4) [43] and other
plaque constituents (oxidized lipoproteins) [44] were also
shown to induce unique macrophage phenotypes with dis-
tinctive characteristics.
Upon activation by Toll-like or analogous receptor stim-
uli, the macrophage will undergo functional maturation that
results in a rapid induction of anti-microbial pathways for
fast killing and clearance of pathogens. Finally, when the
macrophage has fulfilled and survived its inflammatory
task, it will undergo deactivation. In this final phase, the
RM phenotype and its mediators transforming growth
factor-β (TGF-β), IL-10, and lipoxins, are key contributors
to the resolution of inflammation and tissue repair [40].
Macrophage Polarization and Disease
Macrophage subtypes have the capacity to switch from one
phenotype to another as stimuli from the micro-environment
change. Recently, such plasticity was elegantly demonstrat-
ed in a murine kidney ischemia-reperfusion model [45￿].
Whereas initially pro-inflammatory CAMs were recruited
to the kidney, later time points saw previously attracted
macrophages switch to an MR
+-AAM phenotype, signaling
the resolution of inflammation and repair. Similar reports
were made with regard to other disease states, as for instance
in metabolic disease. Adipose tissue macrophages in lean
mice resemble an AAM phenotype that supports adipocyte
function and insulin sensitivity [46]. Obesity, however,
switches the macrophage balance to a CAM phenotype as
the result of inflammasome activation by various danger
signals from adipocytes, thereby promoting inflammation
and insulin resistance [47, 48]. In analogy to this dichotomy,
differential macrophage function has been reported to influ-
ence the course of various other conditions, such as cancer
and infectious disease [34, 49].
Likewise, in atherosclerosis, evidence implies that the
balance of macrophage polarization is crucial in determining
plaque outcome [49–51]. Following the progression of ath-
erosclerosis over time, it was shown that plaque macro-
phages in early lesions express arginase-1 (indicative of
AAMs), whereas at later time points the expression of
arginase-2 (referred to as a CAM marker) predominated in
the plaque [52]. More recently, phenotypic switching in
atherosclerosis was described upon induction of disease
regression [53￿￿]. Here, plaque macrophages restrained
pro-inflammatory marker expression (eg, monocyte chemo-
tactic protein-1 and tumor necrosis factor) and enhanced that
of AAM markers such as arginase-1, MR, and CD163 upon
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order of events in this model still requires clarification (ie,
does phenotypic switching actively contribute to plaque
regression or is it merely a consequence thereof). In human
subjects too, it was shown that symptomatic atherosclerotic
disease of the carotid arteries is associated with a CAM
profile, characterized by high pro-inflammatory cytokine
expression [54]. Moreover, enrichment of CD11c
+-CAMs
over MR
+-AAMs characterizes the epicardial adipose tissue
from patients with manifest coronary artery disease [55].
These reports are consistent with the current hypothesis that
CAMs propagate plaque vulnerability through their inflam-
matory potential, whereas their AAM counterparts are likely
to benefit plaque stability and regression through a repertoire
of repair and fibrotic functions. From this perspective, Fig. 1
provides a schematic overview of the inducers, transducers,
and effector functions of these macrophage populations in
atherosclerosis development.
Although murine macrophage subtypes are well charac-
terized, the translation to human pathophysiology is not
straightforward. Where polarized macrophage subsets in
mice can be easily distinguished based on their arginine-
metabolizing enzyme expression (i.e. iNOS and arginase-1
for CAMs and AAMs respectively), in vitro polarized hu-
man macrophages do not express arginase-1 and fail to
produce NO in amounts comparable to that of mouse macro-
phages [57]. In addition, markers like Ym1 and Fizz1,
which are excellent for AAM detection in mice, are not
expressed in humans [35]. Circumventing these issues
through identification of generally more favorable markers
of human tissue macrophages will prove an important step
in translational atherosclerosis research.
Transcription Factors in Macrophage Subsets
To achieve expression of the aforementioned surface marker
and cytokine profiles, different macrophage subsets are
known to employ distinct signaling pathways (Fig. 1). These
cascades usually activate certain transcription factors that
effectively induce expression of archetypal genes, thereby
accounting for the translation of external polarizing cues
into a specific subtype [58]. Clearly, this designates tran-
scription factors as important players in macrophage polar-
ization that may represent an attractive alternative to surface
markers for discerning macrophage populations in vivo.
Moreover, these pathways may eventually yield suitable
targets for the inhibition, depletion, or stimulation of a
particular phenotype. An overview of transcription factors
associated to macrophage heterogeneity and their functional
Fig. 1 Molecular regulation of
macrophage subsets. From the
top down are indicated key
external factors that drive
macrophage polarization either
to the classically activated
macrophage (CAM) direction
(left side) or to the alternative
activated macrophages/
regulatory macrophages (AAM/
RM) direction (right side), the
receptors involved,
transcription factors that
regulate CAM or AAM/RM,
and some key markers that
characterize the subsets. At the
bottom, implications of the
subsets for atherosclerosis are
indicated, which are discussed
in more detail in two recent
reviews [49, 56]
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as described below, can be found in Table 1.
STAT Signaling
Signal transducers and activators of transcription (STATs)
are crucial transcription factors in the determination of mac-
rophage phenotype. IFNγ signaling will lead to downstream
phosphorylation and activation of STAT1. Macrophages
lacking this mediator are unable to express a full CAM
phenotype, as they fail to produce nitric oxide (NO) and
have diminished expression of IL-12 and major histocom-
patibility complex (MHC) class II [59]. In murine athero-
sclerosis, macrophage STAT1 deficiency leads to attenuated
atherosclerosis, resulting from a decrease in macrophage
lipid accumulation, macrophage apoptosis, and plaque ne-
crosis [60, 61]. IL-4 and IL-13, inducers of the AAM
phenotype, also signal via JAK-STAT pathways. Both cyto-
kines lead to the activation of STAT6. STAT6 signaling was
shown to be necessary for the expression of many AAM
markers, like arginase-1 [62], but has not been directly
linked to atherosclerosis development.
NF-κB Signaling
Nuclear factor κB( N F - κB) is a key regulator of the initiation
and resolution of inflammation [63]. NF-κB activation, more
specifically that of its subunit p65, is a hallmark of classical
Table 1 The role of transcription factors in macrophage polarization and atherosclerosis
Gene Linked? Model Findings Refs
Classically activated macrophage
STAT1 Yes ApoE
-/-+LDLR
-/-; BMT Hematopoietic STAT1 deficiency leads to decreased plaque sizes [59–61]
NF-κB p65 Yes Human plaques The presence of activated NF-κB p65 in human atherosclerotic
plaques was demonstrated
[64]
IRF1 Yes Human lymphocytes IRF-1 expression was increased in lymphocytes from patients with
acute coronary syndrome
[72, 74]
IRF5 No N/A N/A [70, 71]
NFAT5 Yes ApoE
-/- NFAT5 expression was highly expressed in murine atherosclerotic
lesions
[82, 83]
SOCS1
a Yes Human plaques SOCS1 and SOCS3 are highly expressed by vascular smooth
muscle cells and macrophages in inflammatory regions
[84, 85]
SOCS3 Yes ApoE
-/- SOCS3 targeting oligonucleotides exacerbated the atherosclerotic
process
[85, 86]
Regulatory macrophage
STAT3 Yes LDLR
-/-; adenovirus Adenovirus expression of human STAT3 lowers aortic inflammatory
cell infiltration
[87, 88]
Alternatively activated macrophage
STAT6 No N/A N/A [62]
NF-κB p50 Yes LDLR
-/-; BMT p50 deletion in bone marrow cells leads to more inflammatory and
smaller lesions
[67, 68]
IRF3 No N/A N/A [41]
IRF4 No N/A N/A [69]
PPARγ Yes Human monocytes; IHC human
plaques
PPARγ activation protects against atherosclerotic plaque formation
in humans
[75, 76, 81￿]
LXRα Yes LDLR
-/-; lentivector and human
plaques
Macrophage LXRα gene therapy ameliorates atherosclerosis in
LDLR
-/- mice and LXRα was found increased during regression.
In contrast, human AAM plaque macrophages were shown to have
decreased levels of LXRα.
[77, 79, 81￿]
Cebpb No N/A N/A [89]
KLF2 Yes KLF2
+/- ApoE
-/- Hemizygous KLF2 deficiency increased atherosclerosis in
apoE
-/- mice
[90, 91]
KLF4 No N/A N/A [92]
SOCS1
a Yes Human plaques SOCS1 and SOCS3 are highly expressed by vascular smooth
muscle cells and macrophages in inflammatory regions
[84, 85]
a Involved in both AAM as CAM signaling
ApoE—apolipoprotein E; BMT—bone marrow transplantation; Cebpb—CCAAT/enhancer-binding protein beta; IHC—immunohistochemistry;
IRF— Interferon regulatory factors; KLF—Krüppel-like factor; LDLR—low-density lipoprotein receptor; LXR—liver X receptor; N/A— not
applicable; NFAT—nuclear factor of activated Tcells; PPAR—peroxisome proliferator-activated receptor; SOCS—suppressor of cytokine signaling
proteins; STAT— signal transducers and activators of transcription
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smooth muscle cells, and macrophages in human atheroscle-
roticlesions[64].However,itsactivationissubjecttomultiple
levels of (inhibitory) regulation that fine-tune macrophage
function. Interestingly, attempts to inhibit NF-κBa c t i v i t yb y
deleting inhibitor of NF-κB kinase (IKK) 2, the kinase that
activates NF-κB, yielded unexpected outcomes. IKK2 was
shown to inhibit STAT1 signaling in macrophages, thereby
affecting IL-12, iNOS, and MHC class II expression [65].
Therefore, IKK2 deletion did not diminish polarization to-
wards the CAM phenotype, but instead encouraged certain
CAM characteristics through enhanced STAT1 activity. As
such,macrophage-specificdeletionofIKK2inatherosclerosis
resulted in reduced NF-κB activity but an increased athero-
sclerotic plaque size [66].
Conversely, the p50 subunit of NF-κB was recently iden-
tified as a key regulator of the AAM phenotype both in vitro
as in vivo [67]. In line, it was shown that targeted deletion of
the p50 subunit in macrophages in atherosclerosis led to
more inflammatory lesions. Surprisingly, these lesions were
smaller in size, which was linked to a reduced uptake of
oxidized LDL in activated p50-deficient macrophages [68].
IRF Signaling
Interferon regulatory factors (IRFs) are important mediators
of macrophage polarization and several family members
have been reported in relation to a specific phenotype.
IRF4 was shown to be a key transcription factor controlling
AAM polarization and its associated gene expression profile
[69]. High expression of IRF5 was observed in CAMs and
subsequently described as a central mediator in TLR signal-
ing pathways. Here, it will directly activate the transcription
of pro-inflammatory genes and repress anti-inflammatory
IL-10 expression [70, 71]. Likewise, IRF1 was shown to
cooperate with NF-κB in the induction of several pro-
inflammatory cytokines [72]. Moreover, by antagonizing
IRF4 function [73], IRF1 can also be classified as an im-
portant mediator in CAM signaling. Although the role of
IRFs in atherosclerosis is still to be determined, lympho-
cytes from patients with acute coronary syndromes display
increased IRF-1 expression, linking this transcription factor
to cardiovascular risk [74].
PPAR and LXR Signaling
Another transcription factor found to be crucial for murine
AAM polarization is peroxisome proliferator-activated re-
ceptor (PPAR) γ, a nuclear receptor [75]. Also in human
monocytes, it was shown that PPARγ activation skews
towards an AAM phenotype and conveys important func-
tional differences [76]. A closely related nuclear receptor is
liver X receptor (LXR) α, which was found to be of similar
importance in AAM polarization. Besides regulating lipid
metabolism and transport, LXRα enhances arginase-1 ex-
pression and suppresses inflammatory signaling in macro-
phages [77]. Both of these transcription factors fulfill
additional protective roles in experimental atherosclerosis
[78–80], mainly by reducing intra-cellular accumulation of
oxidized LDL [76, 81￿]. Therefore, PPARγ and LXRα
instill macrophages with powerful anti-inflammatory and
metabolic functionalities.
Epigenetic Control of Macrophage Polarization
Through Histone Modifications
In addition to transcriptional control, epigenetic regulation
is essential for a properly directed expression of target
genes. Without modifying the actual genetic code, epigenet-
ic mechanisms affect DNA accessibility to the transcription-
al apparatus to alter gene expression and even mRNA
degradation by microRNAs. Remarkably, the resulting gene
expression patterns can be passed down to daughter cells
upon cell division or even trans-generationally. Epigenetic
regulation can be achieved through DNA methylation (gen-
erally considered a relatively static process), as well as
through applying certain modification to histones, such as
acetylation or methylation. These marks can be changed
very dynamically in response to many environmental
stimuli.
In macrophages, several epigenetic mediators now are
identified as key players in macrophage function and polar-
ization [93]. For instance, Jmjd3, a JmjC family histone
demethylase that erases lysine 27 trimethylation marks on
histone 3, has been shown to specifically bind transcription
start sites of promoters of NF-κB dependent genes. This
would suggest that Jmjd3 provides additional control of
NF-κB-dependent gene expression, although most pro-
inflammatory genes were expressed independently of Jmjd3
[94, 95]. In addition, it has been described that Jmjd3 plays
an essential role in polarization. In response to AAM polar-
ization, Jmjd3 can induce the expression of IRF4, resulting
in the transcription of key AAM marker genes [62, 69].
Recently, the histone deacetylase 3 (HDAC3) was also
found to mediate macrophage polarization, as HDAC3-
deficient macrophages were shown to be hyperresponsive
to polarization with IL-4 [96]. Thus, alternative activation of
macrophages can be controlled at an epigenetic level by
targeting HDAC3 and Jmjd3, suggesting that epigenetic
mediators might evolve to become promising immunomod-
ulatory targets. This notion was recently substantiated by the
finding that the bromodomain and extra terminal domain
family of proteins-inhibitor (I-BET) is able to disrupt chro-
matin complexes responsible for the expression of key in-
flammatory genes during macrophage activation and could
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This indeed very nicely demonstrates that synthetic com-
pounds specifically targeting epigenetic mechanisms can act
as excellent therapeutic agents for immunomodulation. As
future studies further unravel the epigenomic landscape of
macrophage subtypes, we will definitely see the develop-
ment of other immunomodulatory compounds that target
epigenetic regulation of macrophages. Moreover, in experi-
mental atherosclerosis, it was shown that cell-specific
histone methylation modifications and expression of accom-
panying lysine methyltransferases occur in carotid arteries.
More specifically, differences in histone methylation
modifications in vascular endothelial and smooth muscle
cells were described between the offspring of hypercholes-
terolemic and normocholesterolemic mothers [98]. As his-
tone modifications are readily altered in response to
environmental stimuli, they can provide an attractive expla-
nation how diet and lifestyle may contribute to atherosclerosis
susceptibility [99].
Conclusions
Amongst a variety of atherogenic properties, macrophages
direct and amplify the inflammatory response in atheroscle-
rosis and thereby contribute to lesion initiation, progression,
and clinical manifestation. The plaque macrophage pheno-
type is determined by a plethora of micro-environmental
stimuli encountered during the successive phases of macro-
phage development. These factors can trigger activation of
subtype-specific signaling pathways and downstream tran-
scription factors, which are crucial mediators of macrophage
polarization. Additionally, epigenetic modifiers comprise a
relatively novel level of transcriptional regulation that has
been shown to fine-tune the macrophage phenotype. To-
gether, these molecular effectors may govern the critical
balance between distinct macrophage subsets in atheroscle-
rosis. Such modulation could in turn be expected to either
propagate plaque progression or to confer atheroprotective
mechanisms. It therefore remains crucial to improve our un-
derstanding of macrophage heterogeneity in atherosclerosis
and identify the subsets most suitable for intervention.
Key areas for careful consideration in that light include
the longstanding need for better, more specific markers that
characterize human macrophage subsets. However, interspe-
cies differences in atherosclerotic pathogenesis and macro-
phage marker expression currently prevent us from taking
the next step in translational research [100]. Paradoxically,
additional work with animal models will prove indispens-
able to addressing these challenges, because these
approaches allow for specific deletion of transcriptional
regulators involved in macrophage polarization in experi-
mental atherosclerosis. These endeavors will provide us
with great mechanical insight. Subsequently, by isolating
those mediators important to murine polarization and ablat-
ing them in human macrophages, we can identify new
polarization markers or even a polarization-specific gene
profile for macrophage subsets. Alternatively, the activity
of polarizing transcription factors could be used as a mea-
sure of the inflammatory state of atherosclerotic lesions.
Thereby, gene regulation pathways may be valuable for
diagnosis and individual risk assessment, when combined
with lipid profiles and CRP-levels. In the future, one might
even think of monitoring the activity of these pathways to
evaluate the effects of therapeutic intervention.
As such, the exploration of transcription factors and
epigenetic modifiers that uniquely shape the macrophage
phenotype has the ability to advance our insight into the
macrophage polarization paradigm considerably. This
upholds its potential relevance for integration into the diag-
nostic and therapeutic algorithms of human atherosclerosis,
as described above. Ultimately, we expect the greatest ben-
efit from cell type-specific strategies that allow us to gently
shift the plaque macrophage towards a desirable, atheropro-
tective phenotype, possibly by targeting the appropriate
signaling pathways.
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